CA1139203A - Method and reagent for counteracting lipemic interference - Google Patents
Method and reagent for counteracting lipemic interferenceInfo
- Publication number
- CA1139203A CA1139203A CA000348109A CA348109A CA1139203A CA 1139203 A CA1139203 A CA 1139203A CA 000348109 A CA000348109 A CA 000348109A CA 348109 A CA348109 A CA 348109A CA 1139203 A CA1139203 A CA 1139203A
- Authority
- CA
- Canada
- Prior art keywords
- sample
- adsorbent
- polymer
- reagent
- lipids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
Abstract
METHOD AND REAGENT FOR COUNTERACTING LIPEMIC INTERFERENCE Abstract A method and reagent for counteracting lipemic interference in an assay of a lipid-containing sample, e.g. blood. The method includes the steps of: (a) mixing with the sample prior to or during said assay a high surface area, finely-divided adsorbent having an affinity for lipids, and a nonionic, water-soluble polymer, and (b) precipitating adsorbed lipids in said sample. The reagent includes a high surface area finely-divided adsorbent, and a nonionic, water-soluble polymer having a molecular weight of from about 1,000 to 100,000.
Description
~13~3 METHOD AND REAGENT FOR COUNTERACTING
LIPEMIC INTERFERENCE
This invention relates to a method and reagent for counteracting lipemic interference in an assay of a lipid-containing sample, e.g. blood.
It has been found that lipemia of serum caused by increased concentrations of lipids may disturb, or even make impossible, the assaying of such samples using various assay techniques including, for instance, radioimmunoassay, and enzymatic analysis, especially at short wavelengths. For the diagnosis of, e.g., liver disease, myocarid~l infarct or other body condition which is often accompanied by hyperlipemia, the accuracy of these measurements can be adversel~ affecte~ by the presence of lipids in the sample. Clinical Chemistry, Vol. 24, No. 11, 1978, pp. 2062-3. Also, in various radioimmunoassay (RIA) techniques, the presence of increased concentrations of lipids in the sample can interfere with the assay. Typically, this interference may be demonstrated in RIA systems by the presence of either a floating precipitate or a flocculation or both in the supernatant of the reaction medium during separa-tion of antibody-bound from unbound antigen. Such inter-ference tends to greatly diminish the accuracy and reproducibility of results in quantitative RIA techniques.
The present invention is thus concerned with providing
LIPEMIC INTERFERENCE
This invention relates to a method and reagent for counteracting lipemic interference in an assay of a lipid-containing sample, e.g. blood.
It has been found that lipemia of serum caused by increased concentrations of lipids may disturb, or even make impossible, the assaying of such samples using various assay techniques including, for instance, radioimmunoassay, and enzymatic analysis, especially at short wavelengths. For the diagnosis of, e.g., liver disease, myocarid~l infarct or other body condition which is often accompanied by hyperlipemia, the accuracy of these measurements can be adversel~ affecte~ by the presence of lipids in the sample. Clinical Chemistry, Vol. 24, No. 11, 1978, pp. 2062-3. Also, in various radioimmunoassay (RIA) techniques, the presence of increased concentrations of lipids in the sample can interfere with the assay. Typically, this interference may be demonstrated in RIA systems by the presence of either a floating precipitate or a flocculation or both in the supernatant of the reaction medium during separa-tion of antibody-bound from unbound antigen. Such inter-ference tends to greatly diminish the accuracy and reproducibility of results in quantitative RIA techniques.
The present invention is thus concerned with providing
2~ a method for either eliminating or minimizing such inkerference caused by the presence of lipids, and especially high levels of such lipids, in a sample to be assayed.
~' ~139~/~3 Accordingly, the present invention relates to a method for counteracting lipemic interference in an assay of a lipid-containing sample, which comprises:
(a) mixing with the sample prior to or during said assay a high su.face area, finely-divided adsorbent having a~ affinity for lipids in a minor amount suffi-cient to adsorb lipids present in the sample, and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of lipids in said sample, and (b~ precipitating adsorbed lipids in said sample. Mixing of the adsorbent and polymer may be accomplished by various means so long as thorough mixing with the sample is accomplished. Precipitation of adsorbed lipids may also be by various known means although centrifuging is preferred. After precipita-tion of adsorbed lipids, the precipitate may, if desi~ed, be separated from the supernatant where, for instance, the adsorbent is added prior to the assay, although actual separation is not necessary, for instance, where adsorbent is added during the actual assay.
The present invention also relates to a reagent useful for counteracting lipemic interference in an assay of a lipid-containing sample. The reagent contains a high surface area, finely-divided adsorbent having a high affinity for lipids in a minor amount sufficient to adsorb interfering lipids, and a nonionic, water-soluble polymer having a molecular weight of from about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of adsorbed lipids present in the sample. The reagent may be prepared, for instance, by ultrasonic mixing of a polymer-adsorbent suspension in an aqueous solution having a pH of about 4 to 10.
As used herein, the term lipid refers to any one or more of a group o substances that in general are soluble 11~9~`03 in ether, chloroform, or other solvents for fats but are only sparingly soluble in water, that with proteins and carbohydrates constitute the principal structural components of cells, and that are considered to include fats, waxes, phosphatides, cerebrosides, and related and derived compounds and may even include steroids and carotenoids. In general, according to the invention, the lipid interference of a lipid-containing sample may be reduced at least to a sufficiently low level so that an assay can be performed on the sample without substantial interference from lipids.
Although the sample may be any lipid-containing biological fluid to be assayed, typically it may be whole blood or a blood fraction such as blood serum or blood plasma, all of which may contain lipids in sufficient quantity to interfere with an assay to be performed on the sample. Also, urine may be ccnveniently treated using the method of the present invention, and assays subsequently performed on the urine sample may be improved.
The adsorbent used in the present invention may be the various high surface area, particulate adsorbents having a high affinity to lipids. These materials are finely divided and generally the particle size is sufficiently small for the solids to become suspended in the sample to an extent that precipitation of solids from the suspension would occur at an unduly slow rate, if to any material extent, in a reasonable time period. Typi-cally, the major portion of such particulate adsorbents may have a particle size of less than about 50 microns, preferably less than about 20 microns, say about 15 nanometers or smaller. The adsorbents may be character-ized by a total surface area of at least about 50 square meters per gram, perferably about lO0 to 400 square meters per gram, for instance about 300 square meters per gram. Such adsorbents include charcoal, silica gel, talc, bentonite, clay base materials, alumina base materials, 1~3~32~3 magnesia base materials, and cellulose base materials, although silica gel and talc are preferred. Talc is finely powdered, hydrous magnesium silicate. Silica gel is colloidal silica, made by coagulation of hydrated silica, resembling coarse white sand in appear-ance. The adsorbent may be mixed with the lipid-contain-ing sample in a minor amount sufficient to adsorb a substantial amount of the lipids present in the sample, although the amount may vary depending upon the concentra-tion of lipids in the sample to be removed. ln general, less than about 40, preferably about 0.5 to 20, milligramsof adsorbent per milliliter of sample may be provided in the sample.
The nonionic, water-soluble polymer of the invention may have a molecular weight of about 1,000 to 100,000, preferably about 3,000 to 8,000, and it may be mixed with the lipid-containing sample in a minor amount sufficient to accelerate precipitation of adsorbed lipids in the sample, e.g. less than about 100 mg., about 5 to 80 mg., per ml. of sample. Examples of such polymers include polyethylene glycols and Dextrans, as well as other non-ionic, water-soluble polymers. Frequently, the polymers may contai~ two or more hydroxyl groups and can be termed polyhydroxy-containing polymers. Polyethylene glycols and Dextran are preferred. Dextran is a polysaccharide produced by bacteria growing on a sucrose substrate composed of -D-glucopyranosyl units. Preferred Dextran is Dextran-70 which has a molecular weight of about 70,000.
A preferred polyethylene glycol is PEG-6000 havin~ a molecular weight of about 6,000-7,50Q .
The method of the present invention finds applica-tion in those radioimmunoassay techniques involving a lipid-containing sample where the separation of antibody-bound antigen from unbound antigen is desired. The method finds particular application to the recently-discovered separation technique which employs a nonionic, water-soluble polymer, such as polyethylene glycol as a 1~392~3 precipitating agent for separating the antibody-bound from unbound antigens in RIA techniques. The method of the present invention, for instance, may be applied to the so-called double antibody RIA technique where a serum sample which contains lipids is reacted with a first antibody specific to an antigen in the serum in a reaction medium having a radiolabeled antigen in a known amount, after which a second antibody which is not specific to the antigenO but which is specific to the first antibody, is added to the medium resulting in a mutual agglomeration of the first antibodies bound to antigen and second antibodies to provide a product of sufficient molecular size to be capable of separation by centrifugation. The use of an adsorbent for lipids eliminates the interference caused by lipids during separation of bound and free antigens.
In an embodiment of the present invention, a lipid-containing serum sample to be assayed treated by a method which includes the steps of ~a) mixing with the sample prior to the assay or even during the assay a high surface area, finely-divided adsorbent having an affinity for lipids in an amount sufficient to adsorb lipids present in the sample, and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in an amount sufficient to accelerate preci-pitation of adsorbed lipids in said sample, and (b) precipitating adsorbed lipids in said sample. The adsorbent and polymer may be mixed as a single reagent or as separate reagents, in which event the polymer can be added first. Whether the single reagent embodiment or double reagent embodiment is employed, the adsorbent and polymer are preferably diluted for the reagent(s) in an aqueous buffer to a sufficient extent to facilitate mixing with the sample, e.g. to a concentration of about 0.01% to 5%, preferably 0.05% to 2% by weight of adsorbent and 1% to 15%, preferably 3% to 10% by weight of polymer.
~' ~139~/~3 Accordingly, the present invention relates to a method for counteracting lipemic interference in an assay of a lipid-containing sample, which comprises:
(a) mixing with the sample prior to or during said assay a high su.face area, finely-divided adsorbent having a~ affinity for lipids in a minor amount suffi-cient to adsorb lipids present in the sample, and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of lipids in said sample, and (b~ precipitating adsorbed lipids in said sample. Mixing of the adsorbent and polymer may be accomplished by various means so long as thorough mixing with the sample is accomplished. Precipitation of adsorbed lipids may also be by various known means although centrifuging is preferred. After precipita-tion of adsorbed lipids, the precipitate may, if desi~ed, be separated from the supernatant where, for instance, the adsorbent is added prior to the assay, although actual separation is not necessary, for instance, where adsorbent is added during the actual assay.
The present invention also relates to a reagent useful for counteracting lipemic interference in an assay of a lipid-containing sample. The reagent contains a high surface area, finely-divided adsorbent having a high affinity for lipids in a minor amount sufficient to adsorb interfering lipids, and a nonionic, water-soluble polymer having a molecular weight of from about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of adsorbed lipids present in the sample. The reagent may be prepared, for instance, by ultrasonic mixing of a polymer-adsorbent suspension in an aqueous solution having a pH of about 4 to 10.
As used herein, the term lipid refers to any one or more of a group o substances that in general are soluble 11~9~`03 in ether, chloroform, or other solvents for fats but are only sparingly soluble in water, that with proteins and carbohydrates constitute the principal structural components of cells, and that are considered to include fats, waxes, phosphatides, cerebrosides, and related and derived compounds and may even include steroids and carotenoids. In general, according to the invention, the lipid interference of a lipid-containing sample may be reduced at least to a sufficiently low level so that an assay can be performed on the sample without substantial interference from lipids.
Although the sample may be any lipid-containing biological fluid to be assayed, typically it may be whole blood or a blood fraction such as blood serum or blood plasma, all of which may contain lipids in sufficient quantity to interfere with an assay to be performed on the sample. Also, urine may be ccnveniently treated using the method of the present invention, and assays subsequently performed on the urine sample may be improved.
The adsorbent used in the present invention may be the various high surface area, particulate adsorbents having a high affinity to lipids. These materials are finely divided and generally the particle size is sufficiently small for the solids to become suspended in the sample to an extent that precipitation of solids from the suspension would occur at an unduly slow rate, if to any material extent, in a reasonable time period. Typi-cally, the major portion of such particulate adsorbents may have a particle size of less than about 50 microns, preferably less than about 20 microns, say about 15 nanometers or smaller. The adsorbents may be character-ized by a total surface area of at least about 50 square meters per gram, perferably about lO0 to 400 square meters per gram, for instance about 300 square meters per gram. Such adsorbents include charcoal, silica gel, talc, bentonite, clay base materials, alumina base materials, 1~3~32~3 magnesia base materials, and cellulose base materials, although silica gel and talc are preferred. Talc is finely powdered, hydrous magnesium silicate. Silica gel is colloidal silica, made by coagulation of hydrated silica, resembling coarse white sand in appear-ance. The adsorbent may be mixed with the lipid-contain-ing sample in a minor amount sufficient to adsorb a substantial amount of the lipids present in the sample, although the amount may vary depending upon the concentra-tion of lipids in the sample to be removed. ln general, less than about 40, preferably about 0.5 to 20, milligramsof adsorbent per milliliter of sample may be provided in the sample.
The nonionic, water-soluble polymer of the invention may have a molecular weight of about 1,000 to 100,000, preferably about 3,000 to 8,000, and it may be mixed with the lipid-containing sample in a minor amount sufficient to accelerate precipitation of adsorbed lipids in the sample, e.g. less than about 100 mg., about 5 to 80 mg., per ml. of sample. Examples of such polymers include polyethylene glycols and Dextrans, as well as other non-ionic, water-soluble polymers. Frequently, the polymers may contai~ two or more hydroxyl groups and can be termed polyhydroxy-containing polymers. Polyethylene glycols and Dextran are preferred. Dextran is a polysaccharide produced by bacteria growing on a sucrose substrate composed of -D-glucopyranosyl units. Preferred Dextran is Dextran-70 which has a molecular weight of about 70,000.
A preferred polyethylene glycol is PEG-6000 havin~ a molecular weight of about 6,000-7,50Q .
The method of the present invention finds applica-tion in those radioimmunoassay techniques involving a lipid-containing sample where the separation of antibody-bound antigen from unbound antigen is desired. The method finds particular application to the recently-discovered separation technique which employs a nonionic, water-soluble polymer, such as polyethylene glycol as a 1~392~3 precipitating agent for separating the antibody-bound from unbound antigens in RIA techniques. The method of the present invention, for instance, may be applied to the so-called double antibody RIA technique where a serum sample which contains lipids is reacted with a first antibody specific to an antigen in the serum in a reaction medium having a radiolabeled antigen in a known amount, after which a second antibody which is not specific to the antigenO but which is specific to the first antibody, is added to the medium resulting in a mutual agglomeration of the first antibodies bound to antigen and second antibodies to provide a product of sufficient molecular size to be capable of separation by centrifugation. The use of an adsorbent for lipids eliminates the interference caused by lipids during separation of bound and free antigens.
In an embodiment of the present invention, a lipid-containing serum sample to be assayed treated by a method which includes the steps of ~a) mixing with the sample prior to the assay or even during the assay a high surface area, finely-divided adsorbent having an affinity for lipids in an amount sufficient to adsorb lipids present in the sample, and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in an amount sufficient to accelerate preci-pitation of adsorbed lipids in said sample, and (b) precipitating adsorbed lipids in said sample. The adsorbent and polymer may be mixed as a single reagent or as separate reagents, in which event the polymer can be added first. Whether the single reagent embodiment or double reagent embodiment is employed, the adsorbent and polymer are preferably diluted for the reagent(s) in an aqueous buffer to a sufficient extent to facilitate mixing with the sample, e.g. to a concentration of about 0.01% to 5%, preferably 0.05% to 2% by weight of adsorbent and 1% to 15%, preferably 3% to 10% by weight of polymer.
3 ~ L 3~ i3 The serum sample which contains lipids may be tested by radioimmunoassay for the presence of prostatic acid phosphatase wherein separation of antibody-bound antigen from unbound antigen is accomplished by the double-antibody technique. A nonionic, water-soluble polymer, and an adsorbent are provided in a reaction medium, and an immunoprecipitation reaction between a first water-soluble antibody bound to antigen and a second water-soluble antibody which is not specific to the antigen but is specific to the first antibody is accelerated.
An example of the latter technique for accelerating such immunoprecipitation wherein polyethylene glycol is provided as the polymer is disclosed in U.S. No. 4,298,592, issued November 3, 1981. The accuracy of an assay performed on the lipid-containing sample may be advantageously facilitated and the presence of a floating precipitate or a flocculation in the supernatant or both may be avoided or substantially minimized.
In another embodiment, a similar technique is applied to lipemic serum to be tested for creatine phosphokinase by substantially the same double antibody RIA technique described above in connection withprostatic acid phosphatase.
It has also been found that lipid-containing samples, such as blood serum, can interfere with chemical analyses of sample components, for instance photometric measures of enzyme activities at short wavelengths, and in an embodiment of the present invention/ the method is used to treat a sample to eliminate or reduce lipemic interference in such chemical analyses.
In the method of the present invention, the high surface area, particulate adsorbent having an affinity for lipids and the nonionic, water-soluble polymer may be provided for mixing with a sample to be assayed as a single reagent or as separate reagents. When a single ~`?
1~L3~
reagent is provided, the adsorbent and polymer may be preferably suspended in an aqueous medium that may be buffered at a pH of about 4 to 10. The adsorbent is provided in a minor amount sufficient to adsorb inter-fering lipids in a sample, e.g. about 0.01% to 5% by weight, preferably about 0.05% to 2% by weight, and the polymer is pro~tided in a minor amount sufficient to accelerate precipitation of adsorbed lipids present in the sample, e.g. about 1% to 15% by weight, preferably about 3% to 10%. These amounts of adsorbent and polymer are based on their total amount. Where the adsorbent and polymer components are provided for mixing with a sample as separate reagents 7 typically the active ingredient in each, e.g., adsorbent and polymer, respec-tively, may be preferably suspended in an aqueous medium that may be similarly buffered to a pH described above with respect to the single reagent embodiment. Amounts in the ranges noted above with respect to the active ingredients may be provided in each reagent as can be employed in the single reagent. Where separate reagents are provided, it is preferred that the pol~mer-containing reagent be added to the sample prior to addition of ~he adsorbent-containing reagent.
Examples of buffers which may be used in the above single reagent, adsorbent-containing reagent and polymer-containing reagent include Tris, a commercially-available, aqueous solution containing tris (hydroxymethyl) amino-methane, Barbitol, a commercially-available, aqueous solution of 5,5-diethyl barbituric acid, and other well-known buffers.
The following example will further illustrate the invention applied in creatine phosphokinase-MB (CPK-MB) radioimmunoassay although it will be appreciated that the invention is not limited to this specific example.
Lipemic serum samples from four patients (A,B,C & D) are provided for testing, in two series of quantitative 1~3~
tests for creatine phosphokinase-~ (CPK-MB). The normal level of CPK-MB in human serum is 0-10 IU/l.
In one series, CPK-MB is determined with treatment according to the invention during the assay with silica gel, an adsorbent having affinity for lipids. In another series, also detailed below, silica is omitted.
In the first series in each of four tubes, a radio-immunoassay reaction medium was prepared containing 0.2 ml. lipemic human serum (separate samples A, B, C and D in each tube). Each tube also contained 0.1 ml. first antibody reagent (goat anti-CPK-Bs) and 0.1 milliliter I-125 labeled CPK-BB solution. After incubation, to each tube was added a second antibody reagent containing 8.4%
polyethylene glycol having a molecular weight of about 6,000, a one to 350 dilution of a secondary antiserum (rabbit anti-goat gamma globulin~ 0.1% Triton X-10~, 0.1%
NaN3 and 1 mg./ml. QUSO G32 silica (a silica gel commer-cially available from Philadelphia Quartz Co.). After mixing,each of the tubes was subjected to centrifugation without any incubation. The supernatant Ifree antigen) was decanted and the precipitate containing antigen-antibody complex was measured for radioactivity. The results are set forth below in the Table~
In the second series, the same procedure set forth above was followed except that silica was eliminated from the reaction medium. The results are set forth below in the Table.
Table CPK-MB CPK-MB
LipemicDetermination Determination Patient without with Samplesilica gel silica gel A 74 IU/l 5.0 IU/l B > 250 IU/l 3.7 IU/l C > 250 IU/l 6.3 IU/l D 26 IU/l 10.0 IU/l 'i''`
* Trade Mark ~3~3 g As illustrated in column 2 in the Table, the determina-tion of CPK-MB based upon measurements of radioactivity for the samples were greatly distorted due to lipemic interference caused by the presence of lipids in the serum samples. This interference was substantially eliminated by the presence of adsorbent for lipids as illustrated by the results set forth in column 3.
An example of the latter technique for accelerating such immunoprecipitation wherein polyethylene glycol is provided as the polymer is disclosed in U.S. No. 4,298,592, issued November 3, 1981. The accuracy of an assay performed on the lipid-containing sample may be advantageously facilitated and the presence of a floating precipitate or a flocculation in the supernatant or both may be avoided or substantially minimized.
In another embodiment, a similar technique is applied to lipemic serum to be tested for creatine phosphokinase by substantially the same double antibody RIA technique described above in connection withprostatic acid phosphatase.
It has also been found that lipid-containing samples, such as blood serum, can interfere with chemical analyses of sample components, for instance photometric measures of enzyme activities at short wavelengths, and in an embodiment of the present invention/ the method is used to treat a sample to eliminate or reduce lipemic interference in such chemical analyses.
In the method of the present invention, the high surface area, particulate adsorbent having an affinity for lipids and the nonionic, water-soluble polymer may be provided for mixing with a sample to be assayed as a single reagent or as separate reagents. When a single ~`?
1~L3~
reagent is provided, the adsorbent and polymer may be preferably suspended in an aqueous medium that may be buffered at a pH of about 4 to 10. The adsorbent is provided in a minor amount sufficient to adsorb inter-fering lipids in a sample, e.g. about 0.01% to 5% by weight, preferably about 0.05% to 2% by weight, and the polymer is pro~tided in a minor amount sufficient to accelerate precipitation of adsorbed lipids present in the sample, e.g. about 1% to 15% by weight, preferably about 3% to 10%. These amounts of adsorbent and polymer are based on their total amount. Where the adsorbent and polymer components are provided for mixing with a sample as separate reagents 7 typically the active ingredient in each, e.g., adsorbent and polymer, respec-tively, may be preferably suspended in an aqueous medium that may be similarly buffered to a pH described above with respect to the single reagent embodiment. Amounts in the ranges noted above with respect to the active ingredients may be provided in each reagent as can be employed in the single reagent. Where separate reagents are provided, it is preferred that the pol~mer-containing reagent be added to the sample prior to addition of ~he adsorbent-containing reagent.
Examples of buffers which may be used in the above single reagent, adsorbent-containing reagent and polymer-containing reagent include Tris, a commercially-available, aqueous solution containing tris (hydroxymethyl) amino-methane, Barbitol, a commercially-available, aqueous solution of 5,5-diethyl barbituric acid, and other well-known buffers.
The following example will further illustrate the invention applied in creatine phosphokinase-MB (CPK-MB) radioimmunoassay although it will be appreciated that the invention is not limited to this specific example.
Lipemic serum samples from four patients (A,B,C & D) are provided for testing, in two series of quantitative 1~3~
tests for creatine phosphokinase-~ (CPK-MB). The normal level of CPK-MB in human serum is 0-10 IU/l.
In one series, CPK-MB is determined with treatment according to the invention during the assay with silica gel, an adsorbent having affinity for lipids. In another series, also detailed below, silica is omitted.
In the first series in each of four tubes, a radio-immunoassay reaction medium was prepared containing 0.2 ml. lipemic human serum (separate samples A, B, C and D in each tube). Each tube also contained 0.1 ml. first antibody reagent (goat anti-CPK-Bs) and 0.1 milliliter I-125 labeled CPK-BB solution. After incubation, to each tube was added a second antibody reagent containing 8.4%
polyethylene glycol having a molecular weight of about 6,000, a one to 350 dilution of a secondary antiserum (rabbit anti-goat gamma globulin~ 0.1% Triton X-10~, 0.1%
NaN3 and 1 mg./ml. QUSO G32 silica (a silica gel commer-cially available from Philadelphia Quartz Co.). After mixing,each of the tubes was subjected to centrifugation without any incubation. The supernatant Ifree antigen) was decanted and the precipitate containing antigen-antibody complex was measured for radioactivity. The results are set forth below in the Table~
In the second series, the same procedure set forth above was followed except that silica was eliminated from the reaction medium. The results are set forth below in the Table.
Table CPK-MB CPK-MB
LipemicDetermination Determination Patient without with Samplesilica gel silica gel A 74 IU/l 5.0 IU/l B > 250 IU/l 3.7 IU/l C > 250 IU/l 6.3 IU/l D 26 IU/l 10.0 IU/l 'i''`
* Trade Mark ~3~3 g As illustrated in column 2 in the Table, the determina-tion of CPK-MB based upon measurements of radioactivity for the samples were greatly distorted due to lipemic interference caused by the presence of lipids in the serum samples. This interference was substantially eliminated by the presence of adsorbent for lipids as illustrated by the results set forth in column 3.
Claims (16)
1. A method for counteracting lipemic interference in an assay of a lipid-containing sample,characterized by: (a) mixing with the sample a high surface area, finely-divided adsorbent having an affinity for lipids, in a minor amount sufficient to adsorb lipids present in said sample, and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of adsorbed lipids in said sample; and (b) precipitating said adsor-bent containing adsorbed lipids in said sample.
2. The method of claim 1 characterized in that said adsorbent and said polymer are mixed with said sample prior to said assay.
3. The method of claim 1 characterized in that said adsorbent and said polymer are mixed with said sample during said assay.
4. The method of claim 1 characterized in that said sample is selected from blood serum or blood plasma.
5. The method of claim 1 characterized in that said adsorbent has an average particle size of less than about 50 microns.
6. The method of claim 1, 2 or 3 characterized in that said adsorbent and said polymer are added to said sample simultaneously in a lipid-adsorbing reagent containing said adsorbent and said polymer and an aqueous solution having a pH of about 4 to 10.
7. The method of claim 1, 2 or 3 characterized in that said adsorbent and said polymer are added to said sample as separate reagents, an adsorbent-containing reagent and a polymer-containing reagent, wherein the adsorbent and polymer is each present in its said reagent and said reagents further include an aqueous solution having a pH of about 4 to 10.
8. The method of claim 1 characterized in that the amount of said adsorbent is less than about 40 milligrams of adsorbent per milliliter of sample and the amount of said polymer is less than about 100 milligrams of polymer per milliliter of sample.
9. The method of claim 6 characterized in that lipid-adsorbing reagent is prepared by ultrasonic mixing of said adsorbent and said polymer in said aqueous solution.
10. The method of claim 1 characterized in that said sample is assayed by a double antibody radioimmuno-assay for prostatic acid phosphatase.
11. The method of claim 1 characterized in that said sample is assayed by a double antibody radioimmuno-assay for creatine phosphokinase.
12. The method of claim 1 characterized in that said sample is assayed by a photometric measurement of enzyme activity.
13. A reagent useful for counteracting lipemic interference in the assay of a lipid-containing sample, characterized in that said reagent comprises: a high surface area, finely-divided adsorbent having a high affinity for lipids in a minor amount sufficient to adsorb lipids; and a nonionic, water-soluble polymer having a molecular weight of about 1,000 to 100,000 in a minor amount sufficient to accelerate precipitation of adsorbed lipids in said sample.
14. The reagent of claim 13 characterized in that said polymer is selected from polyethylene glycol and Dextran.
15. The reagent of claim 13 characterized in that said adsorbent is one having an average particle size of less than about 20 microns and is selected from silica gel and talc.
16. The reagent of claim 13 characterized in that said adsorbent and said polymer are in an aqueous solu-tion having a pH of about 4 to 10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/027,388 US4273867A (en) | 1979-04-05 | 1979-04-05 | Method and reagent for counteracting lipemic interference |
US027,388 | 1993-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1139203A true CA1139203A (en) | 1983-01-11 |
Family
ID=21837444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000348109A Expired CA1139203A (en) | 1979-04-05 | 1980-03-21 | Method and reagent for counteracting lipemic interference |
Country Status (5)
Country | Link |
---|---|
US (1) | US4273867A (en) |
EP (1) | EP0017224A1 (en) |
JP (1) | JPS55138657A (en) |
AU (1) | AU539266B2 (en) |
CA (1) | CA1139203A (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2829531A1 (en) * | 1978-07-05 | 1980-01-24 | Heuck Claus Christian Dr Rer N | METHOD FOR QUANTITATIVE DETERMINATION OF A SERUM PROTEIN IN BLUE SERUM AND PLASMA SAMPLES |
US4330622A (en) * | 1979-09-12 | 1982-05-18 | Becton Dickinson & Co. | Elimination of non-microbial turbidity in culture media |
DE3327642A1 (en) * | 1983-07-30 | 1985-02-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD FOR DETERMINING A PARTNER OF AN IMMUNE REACTION AND REAGENT FOR CARRYING OUT THIS METHOD |
US4992365A (en) * | 1984-04-23 | 1991-02-12 | Hyman Edward S | Method of detecting bacteria in urine |
US4673637A (en) * | 1984-04-23 | 1987-06-16 | Hyman Edward S | Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria |
JPS6179164A (en) * | 1984-09-26 | 1986-04-22 | Amano Pharmaceut Co Ltd | Reducing method of antigen-antibody reaction time |
US4698299A (en) * | 1985-02-19 | 1987-10-06 | The Liposome Company, Inc. | Lipid-dependent diagnostic assays |
US4666831A (en) * | 1985-02-19 | 1987-05-19 | The Liposome Company, Inc. | Lipid-dependent diagnostic assays |
IL79945A (en) * | 1986-09-04 | 1991-06-10 | I D L International Diagnostic | Method for the quantitative determination of total cholesterol in blood |
US5466579A (en) * | 1987-12-28 | 1995-11-14 | Psychemedics Corporation | Hair analysis method |
JP2682697B2 (en) * | 1989-03-29 | 1997-11-26 | 積水化学工業株式会社 | Immunoassay reagents and immunoassays |
US5202006A (en) * | 1992-04-17 | 1993-04-13 | Beckman Instruments, Inc. | Analysis of hemoglobin variants by capillary zone electrophoresis |
US7957507B2 (en) * | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
US8232535B2 (en) * | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
KR20080039925A (en) | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | Method and system for adapting a radiation therapy treatment plan based on a biological model |
US8442287B2 (en) * | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
KR20080039920A (en) | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | System and method of evaluating dose delivered by a radiation therapy system |
US20070041498A1 (en) * | 2005-07-22 | 2007-02-22 | Olivera Gustavo H | System and method of remotely directing radiation therapy treatment |
KR20080049716A (en) | 2005-07-22 | 2008-06-04 | 토모테라피 인코포레이티드 | Method and system for evaluating quality assurance criteria in delivery of a treament plan |
JP2009514559A (en) | 2005-07-22 | 2009-04-09 | トモセラピー・インコーポレーテッド | System and method for generating contour structure using dose volume histogram |
EP2532386A3 (en) * | 2005-07-22 | 2013-02-20 | TomoTherapy, Inc. | System for delivering radiation therapy to a moving region of interest |
US20070195922A1 (en) * | 2005-07-22 | 2007-08-23 | Mackie Thomas R | System and method of monitoring the operation of a medical device |
ATE507879T1 (en) | 2005-07-22 | 2011-05-15 | Tomotherapy Inc | SYSTEM FOR ADMINISTERING RADIATION THERAPY TO A MOVING TARGET AREA |
EP1907981A4 (en) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Method and system for evaluating delivered dose |
CA2616299A1 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method of placing constraints on a deformation map and system for implementing same |
EP1907059A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Method of and system for predicting dose delivery |
KR20080044252A (en) | 2005-07-22 | 2008-05-20 | 토모테라피 인코포레이티드 | Method and system for processing data relating to a radiation therapy treatment plan |
US20090041200A1 (en) * | 2005-07-23 | 2009-02-12 | Tomotherapy Incorporated | Radiation therapy imaging and delivery utilizing coordinated motion of jaws, gantry, and couch |
CA2616293A1 (en) | 2005-07-23 | 2007-02-01 | Tomotherapy Incorporated | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch |
US7790401B2 (en) * | 2007-08-06 | 2010-09-07 | Siemens Healthcare Diagnostics | Methods for detection of immunosuppressant drugs |
US9443633B2 (en) | 2013-02-26 | 2016-09-13 | Accuray Incorporated | Electromagnetically actuated multi-leaf collimator |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899298A (en) * | 1972-04-11 | 1975-08-12 | Squibb & Sons Inc | Method and apparatus for angiotensin i determination |
DE2410033C2 (en) * | 1974-03-02 | 1975-09-11 | Merck Patent Gmbh, 6100 Darmstadt | Isolation of substances in aqueous solutions that are soluble in lipophilic solvents |
US3954409A (en) * | 1974-04-22 | 1976-05-04 | Sung Lan Hsia | Method for determining serum cholesterol binding reserve and use in diagnosis |
US4148869A (en) * | 1975-03-06 | 1979-04-10 | Baxter Travenol Laboratories, Inc. | Immunological reagent and method of using same |
US3995019A (en) * | 1975-03-04 | 1976-11-30 | Baxter Travenol Laboratories, Inc. | Diagnostic reagent system |
US4028465A (en) * | 1975-11-10 | 1977-06-07 | Bio-Rad Laboratories | Assay method for serum folate |
US4121975A (en) * | 1976-08-20 | 1978-10-24 | Syva Company | Pretreatment of samples for polyiodothyronine assays |
IL51224A (en) * | 1976-11-19 | 1979-09-30 | Ames Yissum Ltd | Assay method for the quanititative determination of a hapten in aqueous solution |
US4111657A (en) * | 1977-01-21 | 1978-09-05 | American Monitor Corporation | Creatinine assay and reagent system |
US4139604A (en) * | 1977-09-16 | 1979-02-13 | Becton, Dickinson And Company | Separation technique for assays |
DE2816229C2 (en) * | 1978-04-14 | 1983-11-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Methods and means for removing opacities |
EP0006822B1 (en) * | 1978-07-04 | 1982-10-13 | Laboratoires Goella | Method and reagents for measuring the cholesterol content in serum |
-
1979
- 1979-04-05 US US06/027,388 patent/US4273867A/en not_active Expired - Lifetime
-
1980
- 1980-03-21 CA CA000348109A patent/CA1139203A/en not_active Expired
- 1980-04-03 EP EP80101770A patent/EP0017224A1/en not_active Ceased
- 1980-04-03 AU AU57183/80A patent/AU539266B2/en not_active Ceased
- 1980-04-04 JP JP4452880A patent/JPS55138657A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU5718380A (en) | 1980-10-09 |
JPS55138657A (en) | 1980-10-29 |
US4273867A (en) | 1981-06-16 |
AU539266B2 (en) | 1984-09-20 |
EP0017224A1 (en) | 1980-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1139203A (en) | Method and reagent for counteracting lipemic interference | |
JP2701949B2 (en) | Test method and reagent kit therefor | |
US4680274A (en) | Particles for inhibiting non-specific immunoreaction | |
US4672045A (en) | Method for assaying antigen-antibody reactions and reagent thereof | |
EP0471293A2 (en) | Solubilization reagent for biological test samples | |
US5405752A (en) | Enzyme conjugate prepared with insoluble nonoparticle | |
EP0321261A1 (en) | Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand | |
US4299815A (en) | Carcinoembryonic antigen determination | |
CN101446586A (en) | Immunological assay reagents and assay method | |
GB2104216A (en) | Process for detecting presence of auto blocking antibody | |
EP0354954B1 (en) | Reagent and method for detecting rheumatoid factor | |
IE901081L (en) | Enzymatic assay kit and method applicable to whole cells | |
EP0253270B1 (en) | Method for diagnostic immunoassay by solid phase separation | |
EP0713094B1 (en) | Heterogeneous immunoassay with precipitable solid phase | |
JPH04203967A (en) | Rapid measurement method of small amount of constituent | |
JP3618797B2 (en) | Immunoassay | |
EP0534043A2 (en) | Novel antistreptolysin-o reagent for use with Beckman nephelometer system | |
US4631254A (en) | Carcinoembryonic antigen determination | |
JP3444649B2 (en) | Immunoassay reagent and method for producing the same | |
JP3166764B2 (en) | Rapid measurement of trace components | |
EP0184701A2 (en) | A method for determining a ligand | |
JPH07104352B2 (en) | Novel buffer and method for detecting rheumatoid factor | |
CA2005511A1 (en) | Enzyme-labeled receptor composition, diagnostic kit and use in method to determine a ligand | |
JP2001330611A (en) | Immunoassay reagent | |
JPH0280956A (en) | Method for confirming immune agglutination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry | ||
MKEX | Expiry |
Effective date: 20000111 |